Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 230

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 230
---
 issuance costs of the warrant inducement and are treated as equity. The Class G Common Stock Warrants are exercisable for a period of five yearsfrom January 17, 2025, which was the date of stockholder approval. As part of the reverse stock split on January 28, 2025, common stock underlying the Class G Common Stock Warrants was adjusted from 381,004shares of common stock to 1,621,463shares of common stock and the exercise price was reset from $ 16.00to $ 3.7596.

The fair value of the Class G Common Stock Warrants
were estimated using the Black-Scholes option pricing model with the following assumptions:

| Volatility              |     |  100 | % |
| Expected term (years)   |     |    5 |   |
| Risk-free interest rate |     | 4.38 | % |
| Expected dividend yield |     |  0.0 | % |

10. Income Taxes The quarterly provision for or benefit from income taxes is computed based upon the estimated annual effective tax rate and the year-to-date pre-tax loss and other comprehensive loss. The Company did not record a provision or benefit for income taxes during the three months ended March 31, 2025 and 2024, respectively. For the three months ended March 31, 2025 and 2024, the Company recorded non-taxable income of $ 1,417and $ 68,427, respectively, related to a change in the fair value of a warrant liability. The Company incurred taxable losses in 2024 and projects further taxable losses for 2025. The Company did not record a benefit from income taxes because, based on evidence involving its ability to realize its deferred tax assets, the Company recorded a full valuation allowance against its deferred tax assets. F-40

11. Segment Information

ASC 280, “Segment Reporting,” establishes
standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which
separate discrete financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”)
in deciding how to allocate resources and in assessing performance. The Company and the Company’s CODM view the Company’s
operations and manage its business on the basis of reportable segment, which is focused on the prevention and treatment
of disease by developing and commercializing therapeutics that modulate the innate immune system.

The CODM of the Company is the